LVATUG blog

RFB&D is now Learning Ally!

lvatug — Sun, 18 Dec 2011 22:14:11 +0000

This entry is posted by Lauren Tappan:

Learning Ally, formerly Recording for the Blind and Dyslexic^®, a nonprofit volunteer organization, is the nation’s largest educational lending-library serving people who cannot effectively read standard print because of visual impairment, dyslexia or other physical disability.

Memberships cost $99 per year.

http://www.learningally.org/Training-Support/Frequently-Asked-Questions/About-Learning-Ally/47/

You should also check out the free NC Library for the Blind.

http://statelibrary.ncdcr.gov/lbph/

The NCLBPH offers a wide range of books and magazines. The same book and magazine titles found most other public libraries are available for loan. Materials are in large print, braille, or audio formats. The audio materials are either cassette tapes or digital cartridges. Patrons may read one or more formats of their choice. The cassette tapes are recorded at slower speed than commercially available tapes. Thus, the library also loans specially designed cassette players to patrons who request tape service. Special accessories for the cassette players, such as remote controls, breathe switches, and extension levers, are available to those who need them to use the players. Amplifiers are also available; however, require a separate application signed by a doctor that goes to the National Library Service to be filled. The NCLBPH repairs, at no cost, the tape and digital machines loaned to patrons. A toll-free telephone line for use throughout North Carolina is also offered for book requests, quick service and to answer any questions you might have about the service (1-888-388-2460). The Friends of the NCLBPH’s library newsletter,Tar Heel Talk, is provided quarterly to patrons and is available in all formats.

Eylea approved to treat wet age-related macular degeneration

lvatug — Tue, 06 Dec 2011 00:21:28 +0000

Eylea (aflibercept)has been approved by the FDA to treat patients with wet (neovascular) age-related macular degeneration (AMD), a leading cause of vision loss and blindness in Americans ages 60 and older by gradually destroys a person’s sharp, central vision. It affects the macula, the part of the eye that allows people to see fine detail needed to do daily tasks such as reading and driving, as well as being able to read or recognize people’s faces.

Continue reading on Examiner.com Eylea approved to treat wet age-related macular degeneration – Hartford wellness | Examiner.com http://www.examiner.com/wellness-in-hartford/eylea-approved-to-treat-wet-age-related-macular-degeneration#ixzz1fi2V8QxC

ZoomText 10

lvatug — Thu, 01 Dec 2011 11:17:37 +0000

This post is from Lauren Tappan.

I just downloaded a trial version of Zoom Text 10. The advantage of Zoom Text 10 is that you can now read pdf files and it is much easier to have Zoom Text read web links from your e-mail. I started having problems tracking my e-mail messages. . Zoom Text Tech Support was able to help me out and problem solved. I have found Zoom Text Tech Support very helpful in straightening out any program problems.

I also suggest looking up AI Squared Zoom In blog as it has more helpful information for low-vision users.

http://www.aisquared.com/blog/

Retinitis Pigmentosa Facebook Page

lvatug — Tue, 15 Nov 2011 16:01:58 +0000

Retinitis Pigmentosa Awareness Page

http://www.facebook.com/pages/Retinitis-Pigmentosa-Awareness-Page/303807802963828

Study Shows Zeaxanthin Improves Vision in Elderly

lvatug — Tue, 15 Nov 2011 15:54:49 +0000

The Zeaxanthin (zee-uh-zan-thin) and Visual Function Study (ZVF), conducted by eye nutrition pioneer Stuart Richer, PhD, OD at the Veterans Administration Hospital in Chicago, shows scientific evidence that dietary Zeaxanthin improved vision in night driving and fine detail, among others.
The ZVF Study followed 60 elderly veterans with early Age-Related Macular Degeneration (AMD) over a 12-month period that consumed 8 mg of dietary Zeaxanthin daily, showed improvement in the ability to drive at night, recognition of fine detail – an average improvement of 1.5 lines or 8.5 letters on an eye chart, and the disappearance of blind spots.

Stem Cell Therapy for Retinitis Pigmentosa

lvatug — Tue, 08 Nov 2011 11:11:28 +0000

A young Romanian woman named Lydia was disappointed when conventional medicine gave her no hope in treatment of her retinitis pigmentosa. However, Dr. Omar Gonzalez of the Integra Medical Center, located in Mexico, has offered her hope as well as hope for other individuals diagnosed with vision problems including diabetic retinopathy and macular degeneration.

Dr. Omar Gonzalez has devised a stem cell treatment offering an alternative to conventional treatments for the disease. Dr. Gonzalez has designed a proprietary method that involves injection of stem cells behind the eye. Through such procedures, nearly 80% of individuals experienced slowing of the disease process, and approximately 60% have noticed an increase in their peripheral vision. None of the patients treated for retinitis pigmentosa at Integra Medical Center experienced post-treatment side effects, and defined any discomfort to merely “minimal” for up to 12 hours following the injection.

Within 30 minutes following the treatment, Lydia, who previously could hardly see four feet in front of her, could define shapes, people and even the color of their clothing. Lydia finally feels that she has some hope, not only to see her family members, but also to become more self-sufficient and less reliant on others to do things for her.

For more info:

http://www.placidway.com/article/717/Stem_Cell_Therapy_for_Retinitis_Pigmentosa

Macular Degeneration: Hot Topics in Treatment

lvatug — Mon, 07 Nov 2011 12:15:56 +0000

Watch this video on AMD from

American Academy of Ophthalmology 2011

by Diana Do, MD; Julia A. Haller, MD

To watch video, http://www.medscape.com/viewarticle/752736

Vascular Treatment to Prevent Progression of Dry AMD

lvatug — Mon, 07 Nov 2011 11:57:23 +0000

The progressive disease occurs in the dry or early (non-exudative) form and the wet or late (exudative) form. Approximately 30 million people have AMD; 90% of those afflicted have the dry form, for which there is no approved treatment.

Dr. George Chiou determined the way to prevent the progression of dry AMD to wet AMD was to develop formulations that could restore choroidal blood flow, thus returning the natural process of nutrient and waste exchange and stabilization of the Bruch’s Membrane.

MacuCLEAR, Inc. (Plano, Texas) completed a Phase 1b/POC study of a topical agent, MC 1101, that significantly improved choroidal blood flow in eyes affected by AMD.

For more info:

http://www.dddmag.com/article-Vascular-Treatment-to-Prevent-Progression-of-Dry-AMD-11411.aspx

Gene Therapy Trial for Usher’s Syndrome To Begin

lvatug — Tue, 01 Nov 2011 13:25:50 +0000

Oxford BioMedica announced that it had gained approval from the FDA to begin a Phase I/IIa Clinical Trial for a form of Usher’s Syndrome, Type 1B, which leads to progressive retinitis pigmentosa combined with a congenital hearing defect.

Usher syndrome is the most common form of deaf-blindness which affects approximately 30,000-50,000 patients in the US and Europe. One of the most common subtypes is Usher syndrome type 1B. The disease is caused by a mutation of the gene encoding myosin VIIA (MY07A).

The open label, dose escalation Phase I/IIa study will enrol up to 18 patients with Usher syndrome type 1B at the Oregon Health and Science University’s Casey Eye Institute, Portland, Oregon. The study, led by Professor Richard Weleber, will evaluate three dose levels for safety, tolerability and aspects of biological activity and is expected to be initiated by the end of 2011.

For more info:

http://irvaronsjournal.blogspot.com/2011/10/gene-therapy-update-1-first-clinical.html

http://eyedocnews.com/006188-gene-therapy-trial-for-retinitis-pigmentosa-based-on-usher%E2%80%99s-syndrome-to-begin/

Walking Reduces Risk of Age Related Macular Degeneration

lvatug — Mon, 31 Oct 2011 13:22:42 +0000

Recent research out of the University of Wisconsin is confirming that walking regularly assists in the prevention of the disease. TrekDesk treadmill desks get people out of their chairs and moving again which will reduce their odds of developing ARMD.

Women who were the most active registered a 54% lower risk of ARMD. Those who were most active and ate a healthy diet had a 71% decreased risk of developing ARMD. Mares and her colleagues believe that walking and proper diet contributed to reductions in blood pressure, inflammation and oxidative damage which would contribute to the preventative results.

http://www.prweb.com/releases/2011/10/prweb8919604.htm